World Health Organization OKs Multi-dose Maternal RSV Vaccine
The new multi-dose RSV vial is expected to lower costs and simplify global distribution to protect infants from severe respiratory illness.
Category: RSV
RSV
Latest
World Health Organization OKs Multi-dose Maternal RSV Vaccine
The new multi-dose RSV vial is expected to lower costs and simplify global distribution to protect infants from severe respiratory illness.
Read More
AAP Updates RSV, COVID-19 Vaccine Recommendations
AAP recommendations expand second-season RSV protection criteria for children ages 8 to 19 months, alongside updated infant COVID-19 vaccination recommendations.
Read More
IDSA Issues Vaccine Recommendations for 2026-2027
New clinical recommendations emphasize the safety and importance of COVID-19, influenza, and RSV vaccines for individuals with weakened immune systems.
Read More
Merck Wants to Extend RSV Vaccine to Second Season
FDA will review Enflonsia’s ability to protect high-risk children under 2 years of age during their second RSV season.
Read More
NFID Initiative to Improve Respiratory Disease Prevention Messaging
The National Foundation for Infectious Diseases (NFID) launched an initiative to streamline evidence-based information regarding respiratory disease prevention.
Read More
Co-Diagnostics Submits Co-Dx PCR Flu A/B & RSV Test for FDA Clearance
Co-Diagnostics submitted a dual 510(k) premarket notification and CLIA Waiver by Application to the FDA for its Co-Dx PCR Flu A/B & RSV multiplex respiratory test.
Read More
FDA to Review RSV Drug Enflonsia for Children 2 and Younger
Merck is seeking expand approval for its RSV drug Enflonsia to include children under age two through their second year of risk.
Read More
High RSV Hospitalization for Immunocompromised Adults
Adults with weakened immune systems, particularly transplant recipients, face significant risks of severe illness and death from respiratory syncytial virus (RSV).
Read More
Child Respiratory Illnesses Linked to Lower Income, Educational Attainment
Infants exposed to viruses by older siblings face a higher risk of hospitalization and long-term socioeconomic challenges, according to new research.
Read More
COVID-19 Pandemic Shifted Timing of Seasonal Respiratory Surges
A study shows that a loss of immunity caused flu and RSV peaks to occur earlier in the season before returning to pre-pandemic patterns.
Read More
RSV Antiviral Zelicapavir Enters Late-stage Clinical Trials
Enanta Pharma advanced zelicapavir into a registrational Phase 2b/3 clinical trial for adults at high risk of severe RSV outcomes.
Read More
FDA Clears AMDI Fast PCR Respiratory Panel for Point-of-Care Testing
The AMDI Fast PCR System provides point-of-care results for RSV, influenza, and COVID-19 in less than 10 minutes.
Read More
Pediatric Risk Factors for Severe Respiratory Infections
Underlying chronic conditions and hospital transfers are major indicators of severe disease in pediatric patients with respiratory tract infections.
Read More
Maternal RSV Vaccine Cuts Infant Hospitalizations Nearly 70%
Real-world data published in JAMA Network Open confirm the effectiveness of the RSVpreF vaccine in protecting newborns from respiratory syncytial virus.
Read More
Lawsuit Alleges 1960s Infants Given RSV Vaccine Without Consent
The families of two infants who died in the 1960s are suing the federal government alleging the babies received an experimental RSV vaccine without the knowledge or consent of their families, according to a report by The New York Times.
Read More
Maternal RSV Vaccination Cut Infant Hospitalization Risk by 80%
Maternal RSV vaccination reduced infants’ hospitalization risk by more than 80% when administered at least 14 days before birth.
Read More
RSV Vaccine Arexvy Gets Expanded Approval for At-risk Adults 18-49
The expanded approval means Arexvy is now indicated for all adults aged 60 and older, and adults aged 18–59 at increased risk for LRTD caused by RSV.
Read More
ACP: Adults 75+ Should Get a Protein Subunit RSV Vaccine
The American College of Physicians recommends an RSV vaccine for all adults age 75 and older.
Read More
Infant Immune Response May Explain RSV Severity Compared to SARS-CoV-2
A study found that infant immune systems respond very differently to RSV and SARS-CoV-2, with important treatment implications.
Read More
Flowflex 4-in-1 RSV, Flu A/B, COVID Home Test Available
The Flowflex Plus 4-in-1 is the first single home test FDA-cleared for adults and children 6 months or older to test for RSV, influenza A/B, and COVID-19.
Read More
New Evidence Reshapes RSV Prevention Strategies
Recent advances in maternal vaccines and long-acting monoclonal antibodies have broadened the scope of RSV prevention, but questions remain.
Read More
CDC/HHS Remove Vaccines from Childhood Immunization Schedule
The CDC and HHS reduced the federally recommended childhood immunization schedule from 17 to 11 vaccinations, removing shots for seasonal flu and other infectious diseases.
Read More
Nirsevimab Greatly Reduced Severe RSV in Infants
For infants in their first RSV season, the monoclonal antibody Nirsevimab (Beyfortus) was 80% effective against RSV-related ICU admission and 83% effective against acute respiratory failure.
Read More
RSV Awareness Month: Preventing Infant Hospitalizations
For RSV awareness month (October), the American Lung Association is spotlighting new data that show a dramatic decrease in RSV-related hospitalizations among infants.
Read More